To effectively treat these ophthalmic conditions however, the use and efficacy of conventional oph. Various pharmacological agents possess the potential Ously threatened by many ocular pathologies. Optimal vision remains one of the most essential elements of the sensory system continu. RNFL, retinal nerve fiber layer IPL, inner plexiform layer ONL, outer nuclear layer ONH, optic nerve head scale bar: 100 μm. (c) In vivo posterior-segment OCT analysis showing RNFL thinning was significantly reduced at day 7 post laser treatment in the uncaged timolol and authentic timolol-treated eyes. (b) Ex vivo immunofluorescent microscopic analysis showing RGC loss was significantly reduced at day 7 post laser treatment in the uncaged timolol and authentic timolol-treated eyes. (a) In vivo anterior-segment OCT analysis showing the central cornea thickness (indicated by red or blue brackets) was significantly reduced at day 3 post laser treatment in uncaged timolol and authentic timolol-treated eyes, compared to PBS control condition. Uncaged timolol protected ocular structures and significantly reduced corneal edema, retinal ganglion cell loss, and retinal nerve fiber layer thinning associated with glaucoma. Fourth, our lenses are disposable, designed for single day use, and manufactured at a low cost. Third, the lenses allow the patient to passively control the amount of timolol released from the lens - for example, early morning exposure to outdoor sunlight would release enough timolol to maximally reduce the IOP, whereas subsequent periodic exposures to indoor daylight would release sufficient timolol to overcome the effects of its spontaneous dissociation from βARs. Second, the contact lenses inhibit βARs in the eye using only 5.7% of the timolol within a single eye-drop. First, fitted contact lenses exposed to natural daylight release sufficient timolol to sustain the inhibition of βARs over a 10 h period. Our studies highlight several advantages of daylight-mediated release of timolol from lenses compared to eye-drops. Studies conducted in a preclinical mouse model of glaucoma show photoreleased timolol is effective as authentic timolol in reducing IOP. Timolol is coupled to the polymer of the contact lens via a photocleavable caged cross-linker and is released exclusively to the surrounding fluid after the 400-430 nm mediated cleavage of the cross-linking group. Here, we introduce contact lenses that release timolol to the eye throughout the day during passive exposures to natural daylight at a more therapeutically relevant concentration (>3000 ki). This high dose is wasteful and triggers off-target effects that increase medication noncompliance. Timolol is administered using 0.5% eye-drop solutions at >3 × 10⁷ times the inhibitory concentration (ki) for βARs. Timolol, a potent inhibitor of β-adrenergic receptors (βARs), is a first-line drug for decreasing the intraocular pressure (IOP) of patients with glaucoma.
0 kommentar(er)
